NO MAINTENANCE, ADDITIONAL RATE COSTS AMONG TOP PERKS HIGHLIGHTED BY RENTERS IN NEW SURVEY

NO MAINTENANCE, ADDITIONAL RATE COSTS AMONG TOP PERKS HIGHLIGHTED BY RENTERS IN NEW SURVEY

BRISBANE, Australia, Dec. 12, 2024 /PRNewswire/ -- Tenants have declared the perks that will keep them renting for up to another five years in a new survey conducted by Budget Direct Home Insurance. Top of the list is no maintenance costs, with 51.4...

Fintech Abu Dhabi Unites Global Tech Leaders, Reaffirms Abu Dhabi as a Hub for Financial Innovation

Fintech Abu Dhabi Unites Global Tech Leaders, Reaffirms Abu Dhabi as a Hub for Financial Innovation

ABU DHABI, UAE, Dec. 12, 2024 /PRNewswire/ -- Fintech Abu Dhabi returned for its highly anticipated eighth edition, reinforcing its status as the Middle East's biggest fintech festival. Part of Abu Dhabi Finance Week (ADFW), the flagship event...

Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment

Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment

DOVER, Del. and EPALINGES, Switzerland, Dec. 11, 2024 /PRNewswire/ -- Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver...

2024 Understanding China Conference Concludes Successfully: A New Path for Global Understanding of Chinese Modernization

2024 Understanding China Conference Concludes Successfully: A New Path for Global Understanding of Chinese Modernization

GUANGZHOU, China, Dec. 10, 2024 /PRNewswire/ -- The 2024 Understanding China International Conference concluded after three days of insightful discussions, bringing together political leaders, scholars, business executives, and representatives from...

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...

Waters Highlights Continued Progress Towards Sustainability Commitments

Waters Highlights Continued Progress Towards Sustainability Commitments

News Summary: Exceeded its goal of reducing Scope 1 and 2 greenhouse gas emissions by 36% from a 2016 baseline, two years ahead of schedule. Invested in STEM education through the Waters Student Academy and Waters internship program, reaching...

From Innovation to Integrity: Bybit's Take on Digital Asset Regulation at VTIS 2024

From Innovation to Integrity: Bybit's Take on Digital Asset Regulation at VTIS 2024

DUBAI, UAE, Dec. 10, 2024 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, was a prominent participant at the Vietnam Tech Impact Summit (VTIS 2024) in early December. The event brought together global...

Arcfra Partner Day 2024 Successfully Held in Seoul

Arcfra Partner Day 2024 Successfully Held in Seoul

SEOUL, South Korea, Dec. 10, 2024 /PRNewswire/ -- Arcfra Pte. Ltd. (hereinafter referred to as "Arcfra," arcfra.com), a leading innovator in cloud infrastructure and full-stack solutions, hosted its first event for Korean partners on November 27th...

IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH

IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH

SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 10, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies...

U Power and Major Shareholder Chatchaval Jiaravanon Outline Strategic Collaboration for 2025

U Power and Major Shareholder Chatchaval Jiaravanon Outline Strategic Collaboration for 2025

Third-generation member of Thailand's Charoen Pokphand Group and Fortune magazine owner reinforces commitment to U Power's innovative EV battery solutions SHANGHAI, Dec. 9, 2024 /PRNewswire/ -- U Power Limited (the "Company" or "U Power"), today...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • menu
    menu